Best Life Sciences Companies in Hauts de France, France
The 50 best Life Sciences companies in Hauts de France, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Genfit.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Hauts de France
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Genfit Therapeutics for cardiometabolic and neurodegenerative diseases. | $425M | 105 mo ago | Public | Pascal Prigent Chief Executive Officer | 1999 | DrupalPHPZURB Foundation+24 | 1,009 patents Therapeutics for metabolic liver diseases targeting PPAR agonists and ACC inhibition | 1 launch |
| 2 | Alzprotect Developing Tau-protein targeted small molecule drugs for neurodegenerative diseases | $20M | 102 mo ago | Series B | Philippe Verwaerde CEO | 2007 | JoomlaPHPYouTube+6 | 71 patents Benzimidazole small‑molecule therapeutics for sensory and motor neuron disease treatment | — |
| 3 | MDoloris Medical Systems Medical devices for continuous, noninvasive evaluation of pain and analgesia | $15M | 97 mo ago | Series B | Fabien Pagniez CEO | 2010 | WordPressMySQLPHP+17 | — | — |
| 4 | Safe Orthopedics Single use instruments for lumbar Spine surgery | $14M | 67 mo ago | Public | — | 2011 | Apple iCloud MailMicrosoft 365Vue.js+5 | — | — |
| 5 | Lattice Medical Provider of 3D-printed technology for soft tissue reconstruction 32Funding top 31%Growth top 35%Moat top 38%Talent bottom 49% All 7 signals ▾Fundingtop 31% Growthtop 35% Moattop 38% Talentbottom 49% Globalbottom 38% Techbottom 37% Marketbottom 25% Funding: Raised $13.5M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $14M | 9 mo ago | Series B | Julien Payen Co-Founder & CEO | 2017 | WordPressMySQLPHP+16 | — | — |
| 6 | In'Tech Medical Surgical instruments for orthopaedic industry | $9M | 51 mo ago | Acquired | Malpiece Co-Founder | 2000 | Cart FunctionalityJoomlaPHP+20 | — | — |
| 7 | Hemerion Developer of therapeutic solutions for the treatment of cancer | $7M | 14 mo ago | Series A | Maximilien Vermandel Co-Founder & CEO | 2020 | WordPress Block EditorWordPressMySQL+28 | — | 1 partnership |
| 8 | Vaxinano Prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets | $6M | 21 mo ago | Series A | — | 2016 | — | 20 patents Nanoparticle-based delivery of whole inactivated bacteria for vaccine formulations | — |
| 9 | Samabriva Developer of enzymes replacement therapies for the treatment of lysosomal storage disorders | $4M | 31 mo ago | Series A | Alain Huriez Co-Founder & Chairman | 2018 | WordPressMySQLPHP+21 | 13 patents Hairy-root bioreactor systems for producing and harvesting plant secondary metabolites | — |
| 10 | Japet Medical Devices Exoskeleton for the relief from lower back pain | $2M | 105 mo ago | Seed | Damien Bratic Co-Founder & CTO | 2016 | WordPressMySQLPHP+25 | — | — |
| 11 | Lipofabrik Manufactures bacillus species-based lipopeptides | $2M | 88 mo ago | Acqui-Hired | Arnaud Delecroix Founder | 2013 | — | 19 patents Patents concentrated in health & consumer products | — |
| 12 | Par'Immune Developer of parasite-based immunotherapy to treat autoimmune diseases | $2M | — | Deadpooled | Abderrahim Lachgar Co-Founder & CEO | 2017 | — | — | — |
| 13 | Diagast Products and Services for blood transfusion sector | $974K | 62 mo ago | Series A | Diagast Morino CEO & President | 1988 | WordPressMySQLPHP+21 | 45 patents Bead-based in vitro diagnostic platforms for blood typing and multivalent antibody detection. | — |
| 14 | Axorus Developer of artificial retina implant to treat retinitis pigmentosa | $918K | 81 mo ago | Seed | Jean-Damien Louise CEO | 2019 | — | — | — |
| 15 | Seenel Imaging Developer of neuroimaging devices to manage neurological disorders | $465K | 67 mo ago | Funding Raised | Thomas Fontaine Founder & CEO | 2004 | — | 6 patents Obstetric fetal monitoring devices using intrapartum near‑infrared spectroscopy probes | — |
Top 12 Life Sciences companies in Hauts de France
#1
Series B · Loos, Hauts de France · founded 2017$13.5Mraised▾
Provider of 3D-printed technology for soft tissue reconstruction. It also provides the solution for tissue engineering and regenerative medicine by using its propriety 3D-printed bioresorbable scaffold technology and adipose tissue to naturally regenerate. The technology is used for a personalized implant like for breast reconstruction and augmentation among others.
- Oct 2025Grant (prize money)—
- Oct 2025Series B$49.9M
- Oct 2022Series A$7.8M
- Jan 2022Grant (prize money)$2.9M
#2
Series A · Villeneuve d Ascq, Hauts de France · founded 2020 · 14 employees$7.4Mraised▾
Developer of therapeutic solutions for the treatment of cancer. The company is focusing on the development of innovative therapeutics by combining drugs and photonic systems to address oncology fields such as brain tumors and glioblastomas (GBM).
- Jun 2025Series A$7.4M
#3
Series A · Lille, Hauts de France · founded 2016$6.5Mraised▾
Vaxinano is engaged in the development of prophylactic and therapeutic vaccines for infectious diseases, for human and animal health markets. The company is using nanoparticles made of starch and lipids (nanovectors) to develop vaccines. The company's experimental vaccines target toxoplasmosis and tuberculosis and developing anti-bacterial, antiviral and antiparasitic vaccines. The company strategy is to develop vaccines till the proof-of-concept and license to pharma companies for further development. The company also offers contract research services for vaccine research & development including fabrication & characterization of nanoparticles, formulations with active components, optimisation of formulations.
- Oct 2024Series A$6.5M
- Jun 2020Grant (prize money)—
#4
Public · Loos, Hauts de France · founded 1999 · 154 employees$424.8Mraised▾
Genfit engages in the research and development of therapeutics for cardiometabolic and neurodegenerative diseases. Its flagship product Elafibranor is targeted at nonalcoholic steatohepatitis, where it prevents fibrosis production. It is currently in phase 3 clinical trials. The company is also investigating therapeutic interventions in auto-immune, metabolic, inflammatory (chronic inflammatory bowel disease), fibrotic diseases. In addition, Genfit is co-developing therapeutics for mitochondrial dysfunction in type 2 diabetes and kidney disease, in collaboration with Sanofi.
- Oct 2017Post IPO$213M
- Oct 2016Post IPO$38M
- Feb 2016Post IPO$54.2M
- Dec 2014Post IPO$25.9M
#5
Series A · Amiens, Hauts de France · founded 2018 · 10 employees$4.3Mraised▾
Samabriva is developing biologics for the treatment of lysosomal storage disorders. The company is focused on developing enzymes replacement therapies (ERT). Its lead program, SAM-01 is an acid-sphingomyelinase recombinant enzyme for Niemann-Pick disease type A and B.
- Dec 2023Series A$4.3M
#6
Acquired · Rang du Fliers, Hauts de France · founded 2000 · 271 employees$8.6Mraised▾
In'Tech Medical develops and manufactures surgical instruments for orthopaedic industry. Their provide surgical instruments involved in the following areas: Hip, Knee, Spine and Extremities/Trauma. Their product offering includes Bone & Disc Prep, Calipers, Compressors, Cutters, Distractors, Forged & Milled, Grippers and Handles.
- Apr 2022Grant (prize money)$420.6K
- Oct 2021Grant (prize money)$464.4K
- Jul 2017Conventional Debt—
- Jul 2017Series A—
#7
Public · Oisemont, Hauts de France · founded 2011 · 136 employees$13.8Mraised▾
Safe Orthopaedics produces single use instruments for spine surgeries involving the lumbar spine. Its products include the SteriSpine PS, a multiaxial cannulated Pedicle screw system and SteriSpine LC, Lumbar cage system which include Instruments, Cannulated screws, Rod bender, and Lumbar cages. The company is based in Paris and a US subsidiary has been created in 2011. In 2015, Safe Orthopaedics went Public. As of 2016, the company has also started operations in Latin America.
- Dec 2020Post IPO$10.2M
- Jul 2015Post IPO$3.6M
#8
Series B · Loos, Hauts de France · founded 2007 · 10 employees$19.9Mraised▾
Alzprotect is focussed on the development of drugs for neurodegenerative diseases. Its lead candidate AZP2006 is a small molecule which is based on the macroautophagy and modulates the degradation of both APP and Tau protein fragments and thus detoxifies the neurons. The candidate is currently in phase 2 trials for Progressive Supranuclear Palsy (PSP) and in phase 1 studies for Alzheimer's.
- Jan 2018Series B$17.2M
- Jun 2014Series A$2.7M
#9
Series B · Loos, Hauts de France · founded 2010 · 37 employees$14.5Mraised▾
Medical devices for continuous, noninvasive evaluation of pain and analgesia. The objective is to customize the therapeutic to avoid adverse effects of over or under-dosing of these drugs. The company develops medical tools including analgesia monitoring devices. The company provides a technology allowing anesthesiologists and intensivists to effectively personalize analgesia, especially for patients who are not able to communicate. Two products promoting the Analgesia Nociception Index (ANI) technology are registered in Europe, Australia, Russia, Mexico, the Middle East, India and are available in 46 countries.
- Jul 2018Series B$10.6M
- Feb 2016Series A$4M
#10
Acqui-Hired · Villeneuve d Ascq, Hauts de France · founded 2013 · 12 employees$1.8Mraised▾
Lipofabrik is focussed on the production, purification, formulation and sales of biological and biodegradable molecules produced through bioprocesses based on renewable resources. Based on the research program developed at Probiogem laboratory, it is currently working on developing 6 different types of lipopeptides including Fengycin, Plipastatin, Iturin, Lichenysin, Mycosubtilin, Surfactin. It claims that these molecules possess physico-chemical properties and biological activities with the applications as emulsifier, surfactant, antimicrobial and plant systemic resistance inducer.
- Apr 2019Grant (prize money)$1.8M
- Jan 2018Grant (prize money)$60.1K
#11
Series A · Loos, Hauts de France · founded 1988 · 169 employees$974.3Kraised▾
Diagast develops, manufactures and market products related to blood transfusion sector. The company offers a range of automated systems (QWALYS) and related reagents for the blood grouping determination. The company's product portfolio includes - ABD PAD, is a pad based on M-TRAP technology for manual blood grouping; QWALYS range, a fully-automated and high-throughput systems for immunohematology; E.M. Technology (Erythrocytes Magnetized Technology) for Antibody screening and Blood grouping and phenotyping. In addition, the company offers other products including a range of single-use plates for blood grouping and phenotyping and OEM services.
- Jun 2021Grant (prize money)$974.3K
- May 2017Series A—
#12
Seed · Lille, Hauts de France · founded 2016 · 40 employees$2.3Mraised▾
Japet Medical Devices is a developer of devices for the treatment of lower back. It has developed Atlas, an exoskeleton to relieve the pain of lower back. This device is equipped with micro-motors which decompress the spine to relieve the patients. The motors follow the movement of the body to allow physical exercises guided through a ludic interface. The device is intended to be used during daily training sessions, and it is claimed to improve the recovery after a rehabilitation program. As of 2017, the company plans to expand the indication for ambulatory rehabilitation.
- Oct 2017Seed$2.3M
- 2016Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
- Centre NAT RECH Scient10040
- INST NAT Sante RECH MED8292
- Sanofi3990
- Pasteur Institut3416
- Agronomique INST NAT RECH1331
- Cellectis1320
- PF Medicament1203
- Commissariat Energie Atomique1151
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.